Neonatal outcomes

	NICU admission	SGA	LGA	Hypoglycemia	RDS	Hyperbilirubinemia	Sepsis	IVH	NEC	Length of Stay
1H screen	13.57%	8.82%	8.82%	35.29%	54.41%	48.53%	5.88%	1.47%	0.0%	21.8 days
2H screen	13.99%	8.51%	4.26%	19.15%	53.19%	63.83%	6.38%	6.38%	4.26%	30.3 days



274 Association of the Pro12Ala polymorphism of PPARγ2 with mild gestational hyperglycemia and gestational diabetes

Kristin Taylor[1], Paula Lima[2], Rafael Gelaleti[2], Mario Hirata[3], Yuri Sinzato[2], Iracema Calderon[2], Débora Damesceno[2], Marilza Rudge[2]

[1]Brown University Warren Alpert School of Medicine, Women & Infants Hospital of Rhode Island, Obstetrics and Gynecology, Providence, RI, [2]Faculdade de Medicina de Botucatu, UNESP, Distrito de Rubião Jr, Laboratório de Pesquisa Experimental de Ginecologia e Obstetrícia, Botucatu, Brazil, [3]Faculdade de Ciências e Farmacêuticas, Universidade de São Paulo, Departamento de Análises Clínicas e Toxicológicas, São Paulo, Brazil

OBJECTIVE: To determine the prevalence of the Pro12Ala polymorphism in pregnant women with normoglycemia, mild gestational hyperglycemia, and gestational diabetes (GDM).

STUDY DESIGN: Diagnosis of GDM was made using the 100g oral glucose tolerance test according to the ADA criteria. Gestational hyperglycemia was diagnosed using the glycemic profile test, during which a standardized 2,840 calorie diet is administered across five meals, with measurement of glucose levels fasting and two hours following each meal. Mild gestational hyperglycemia was diagnosed with one or more abnormal values of fasting glucose >90 mg/dL or postprandial glucose >130 mg/dL. Genotyping for the Pro12Ala allele was performed on DNA from maternal serum samples by the RFLP method using the BstU1 restriction endonuclease. Patients were classified as Pro/Pro homozygotes (single 244 base pair (bp) segment), Pro/Ala heterozygotes (244, 223, and 21 bp segments), or Ala/Ala homozygotes (223 and 21 bp segments). Genotype frequencies were compared between groups using the Chi-Square test with $p<0.05$ for statistical significance.

RESULTS: One hundred fifty-one pregnant women were included in the study. Fifty-four women were normoglycemic, 32 had mild gestational hyperglycemia, and 65 were classified as GDM. There were no Ala/Ala homozygotes in any group. The frequency of Pro/Ala heterozygotes was significantly lower in women with mild gestational hyperglycemia relative to normoglycemic women (9.4% vs. 17.3%, $p<0.05$), and in women with GDM relative to normoglycemic women (10.9% vs. 17.3%, $p<0.05$). The frequency of heterozygotes did not differ between patients with mild gestational hyperglycemia and GDM.

CONCLUSION: The prevalence of Pro12Ala was higher among normoglycemic women, suggesting that this polymorphism may be protective against hyperglycemia in pregnancy. Further investigation is needed to elucidate the effect of this polymorphism on adverse maternal and neonatal outcomes associated with these conditions.

275 A1C at the first prenatal visit: is it useful?

Lisa Moore[1], Diana Clokey[1]

[1]University of New Mexico, OB/GYN, Albuquerque, NM

OBJECTIVE: To evaluate A1C at the first prenatal visit as a triaging tool for deciding when to test for GDM.

STUDY DESIGN: An A1C was obtained at the first prenatal visit. ADA guidelines were used in which A1C ≥ 6.5% is considered diabetes and an A1C between 5.7-6.4% is glucose intolerance. Enrollment occurred between August 2011 and March 2012. All women had the first prenatal visit prior to 20 weeks. Women with an A1C ≥ 6.5% (group 1) were instructed on diet and daily self monitoring of blood glucose. Women with an A1C between 5.7-6.4% (group 2) were tested immediately for GDM and if necessary, again at 24-28 weeks. Women with an A1C < 5.7% (group 3) were tested at 24-28 weeks. Patients were started on medication if they failed to meet glycemic goals of fasting ≤ 95 mg/dl and 2 hour postprandial ≤ 120 mg/dl.

RESULTS: 296 patients were included in the study. There were 16 patients in group 1. 15/16 (95%) required medication to achieve euglycemia. The mean gestational age at which medication was required in group 1 was early at 14 ± 6 weeks; Postpartum, 14/16 patients (87%) remained diabetic. Group 2 contained 75 patients. 60 patients (80%) were given a diagnosis of GDM and 48 patients (64%) required medication. The mean gestational age at which medication was started in group 2 was 20 ± 7.8 weeks. This is 4 to 8 weeks earlier than if these patients had received testing at the standard time of 24-28 weeks. There were 205 patients in group 3. 18 patients in group 3 (8.7%) were diagnosed with GDM and 13 patients (6%) required medication.

CONCLUSION: A1C at the first prenatal visit can be used to optimize the timing of screening for gestational diabetes. An A1C ≥ 6.5% identifies women with a degree of hyperglycemia consistent with preexisting diabetes who may benefit from diet and daily glucose monitoring. A1C between 5.7-6.4% identifies women with a degree of glucose intolerance who may benefit from early testing. A1C <5.7% is associated with minimal glucose intolerance and testing may be undertaken at the usual 24-28 weeks.

276 Examining gestational weight gain recommendations in diabetic pregnancy

Lorie Harper[1], Ryan Colvin[1], Anthony Odibo[1], Anthony Shanks[1], George Macones[1], Alison Cahill[1]

[1]Washington University in St. Louis, Obstetrics and Gynecology, St. Louis, MO

OBJECTIVE: The Institute of Medicine (IOM) does not make recommendations for gestational weight gain (GWG) specific to diabetic women. We aimed to assess the impact of GWG outside the IOM recommendations on pregnancy outcomes in diabetic women.

STUDY DESIGN: Secondary analysis of a prospective, 4-year cohort of women with gestational or Type 2 diabetes. Women were approached for enrollment at entry to care & excluded for Type 1 DM, multiple gestation, fetal anomalies, unknown body mass index (BMI), unknown GWG & incomplete delivery records. Primary neonatal outcomes were fetal growth restriction (FGR), defined as birthweight <10th percentile on Alexander growth standard, & macrosomia, defined as birthweight >4000g. Maternal outcomes were cesarean delivery (CD) & preeclampsia. Secondary neonatal outcome was a composite of: delivery <37 wks, admission to level 3 nursery, respiratory distress syndrome, shoulder dystocia, 5-minute Apgar≤3, cord pH<7.1, & cord base excess <−12. Women were classified as GWG within (WITHIN), less than (LESS), or greater (MORE) than IOM